drugset
drugset / Trial / NCT02523040

Lenalidomide for Adult Histiocyte Disorders

NCT02523040 ↗

Phase 2 Active not recruiting 12 enrolled Dana-Farber Cancer Institute Celgene Corporation · collab
NaSingle-groupOpen-labelTreatment

Summary

This research study is studying a chemotherapy drug Lenalidomide as a possible treatment for one of three histiocyte disorders: Langerhans cell histiocytosis (LCH), Erdheim-Chester disease (ECD), or histiocytic sarcoma (HS).

Timeline

Start
2015-08
Primary completion
2024-02
Completion
2026-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Lenalidomide Other / unclassified — Oral

Indications

Erdheim-Chester disease Langerhans cell histiocytosis histiocytic sarcoma